Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia

References

• Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301–307.
   PubMed Web of Science ®Google Scholar
• Albus M, Hubmann W, Mohr F, et al. Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study . Eur Arch Psychiatry Clin Neurosci. 2006;256(7):442–451.
   PubMed Web of Science ®Google Scholar
• Gross G. Novel antischizophrenia treatments. Handb Exp Pharmacol. 2012;213(5):13–20.
   Google Scholar
• Bora E. Neurodevelopmental origin of cognitive impairment in schizophrenia. Psychol Med. 2015;45(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030–1040.
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321–330.
   PubMed Web of Science ®Google Scholar
• Jeste SD, Patterson TL, Palmer BW, et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res. 2003;63(1–2):49–58.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018–1028.
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249–258.
   PubMed Web of Science ®Google Scholar
• Ferreira CD, de Souza MGD, Fernández-Calvo B, et al. Neurocognitive functions in schizophrenia: a systematic review of the effects of typical and atypical antipsychotic drugs. Psychol Neurosci. 2016;9(1):12–31.
   Google Scholar
• Han X, Yuan YB, Yu X, et al. The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian Arch Psychiatry. 2014;24(4):169–173.
   PubMedGoogle Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23(1):99–110.
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.
   PubMedGoogle Scholar
• Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214–220.
   PubMed Web of Science ®Google Scholar
• Shi C, Kang L, Yao S, et al. The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res. 2015;169(1–3):109–115.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu M, Guo X, et al. Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients. Neural Regen Res. 2013;8(3):277–286.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl). 2003;169(3–4):404–411.
   PubMed Web of Science ®Google Scholar
• Riedel M, Spellmann I, Schennach-Wolff R, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry. 2010;43(2):50–57.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Sato S, Iwata K, et al. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry Clin Neurosci. 2014;68(6):425–431.
   PubMed Web of Science ®Google Scholar
• Perlick D, Stastny P, Katz I, et al. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry. 1986;143(2):230–232.
   PubMed Web of Science ®Google Scholar
• Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res. 1990;3(2):127–129.
   PubMed Web of Science ®Google Scholar
• Eum S, Hill SK, Rubin LH, et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017;190:129–135.
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Fisher M, Warm H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055–1062.
   PubMed Web of Science ®Google Scholar
• Ang MS, Abdul Rashid NA, Lam M, et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol. 2017;37(6):651–656.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633–647.
   PubMed Web of Science ®Google Scholar
• Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus. 2001;11(5):520–528.
   PubMed Web of Science ®Google Scholar
• Velakoulis D, Wood SJ, Wong MT, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006;63(2):139–149.
   PubMed Web of Science ®Google Scholar
• Antoniades M, Schoeler T, Radua J, et al. Verbal learning and hippocampal dysfunction in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2018;86:166–175.
   PubMed Web of Science ®Google Scholar
• Buchy L, Czechowska Y, Chochol C, et al. Toward a model of cognitive insight in first-episode psychosis: verbal memory and hippocampal structure. Schizophr Bull. 2010;36(5):1040–1049.
   PubMed Web of Science ®Google Scholar
• Cuesta MJ, Jalon EG, Campos MS, et al. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry. 2009;194(5):439–445.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. AJP. 2007;164(7):1061–1071.
   Google Scholar
• Keefe RSE, Davis VG, Harvey PD, et al. Placebo response and practice effects in schizophrenia cognition trials. JAMA Psychiatry. 2017;74(8):807–814.
   PubMed Web of Science ®Google Scholar
• Lesh TA, Niendam TA, Minzenberg MJ, et al. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology. 2011;36(1):316–338.
   PubMed Web of Science ®Google Scholar
• Huang M, Kwon S, He W, et al. Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacol Biochem Behav. 2017;157:16–23.
   PubMed Web of Science ®Google Scholar
• Huang M, Kwon S, Oyamada Y, et al. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav. 2015;138:49–57.
   PubMed Web of Science ®Google Scholar
• Elbe D. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications, third edition. J Can Acad Child Adolesc Psychiatry. 2010;19(3):230.
   Google Scholar
• Sydserff S, Sutton EJ, Song D, et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol. 2009;78(7):880–888.
   PubMed Web of Science ®Google Scholar
• Censits DM, Ragland JD, Gur RC, et al. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res. 1997;24(3):289–298.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176–184.
   PubMed Web of Science ®Google Scholar
• Schuepbach D, Keshavan MS, Kmiec JA, et al. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res. 2002;53(3):249–261.
   PubMed Web of Science ®Google Scholar